TRANSDERMAL NICOTINE FOR SMOKERS WITH SCHIZOPHRENIA

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本项目是进行一项随机、双盲、安慰剂对照研究，比较两种形式的尼古丁替代（高与低）与安慰剂的有效性和临床相关性。本研究的数据将针对一些临床和理论上重要的问题进行分析，包括以下内容：1.尼古丁替代治疗在这一弱势患者群体中的总体有效性，2。两种治疗方法的相对疗效，3。这些治疗方法在同时接受不同类型抗精神病药物治疗的患者中的相对疗效（非典型vs典型），4。可能与戒烟成功相关的药物遗传学因素。5.戒烟对酶1A2的表达和安定药的稳态的影响。戒烟对副作用特征、剂量和患者症状的潜在影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is to conduct a randomized, double-blind, placebo controlled study comparing the effectiveness and clinical relevance of two forms of nicotine replacement (high versus low) with placebo. Data derived from this study will be analyzed in regard to a number of clinically and theoretically important questions, including the following: 1. Overall effectiveness of nicotine replacement treatment in this vulnerable group of patients, 2. Relative efficacy of the two types of treatment, 3. Relative efficacy of these treatment methods in patients who are also treated with different types of neuroleptics (atypical vs typicals), 4. Pharmacogenetics factors that might be associated with the success of smoking cessation. 5. The effect of smoking cessation on the expression of the enzymes 1A2 and the steady state of the neuroleptic and 6. The potential effect of smoke cessation on the side effect profiles, dosing and symptoms of patients.